Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Expected Total Market Size Of The Next-Generation Antibody Therapeutics Industry By The Forecast Year 2029?
The next-generation antibody therapeutics market size has experienced rapid expansion in recent years. It is projected to grow from $6.82 billion in 2024 to $7.56 billion in 2025, at a compound annual growth rate (CAGR) of 10.8%. This historical growth can be ascribed to factors such as the success of monoclonal antibodies, the increasing prevalence of chronic diseases, the approval of antibody-drug conjugates, and the advancements in immunotherapy, gene therapy, and other antibody technologies.
The market for next-generation antibody therapeutics is projected to experience substantial expansion in the coming years. This market is anticipated to reach “$11.34 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 10.7%. Factors contributing to this growth during the projection period include biosimilar development, bispecific antibodies development, nanobody development, patient-centric approaches, immunomodulatory antibodies, expanded applications in autoimmune diseases, and continuous manufacturing. Key trends expected over the forecast period encompass advancements in antibody engineering, digital technologies in antibody design, industry collaborations, advancements in drug delivery systems, and real-world evidence in antibody development.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12678&type=smp
Which Drivers Are Shaping The Next-Generation Antibody Therapeutics Industry’s Market Share?
The future expansion of the next-generation antibody therapeutics market is anticipated to be significantly propelled by the rising occurrence of chronic diseases. These are conditions that persist for a year or longer, often necessitating continuous medical care, restricting everyday activities, or both. Next-generation antibody therapeutics play a crucial therapeutic role for individuals with chronic illnesses by delivering more focused care, which in turn enhances patient outcomes. For instance, in January 2023, the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, projected that by 2050, the number of individuals aged 50 years and older who have at least one chronic illness will surge by 99.5%, rising to 142.66 million. Consequently, the increasing prevalence of chronic diseases is a key factor driving the growth of the next-generation antibody therapeutics market.
What Are The Emerging Segments Gaining Attention In The Next-Generation Antibody Therapeutics Market?
The next-generation antibody therapeuticsmarket covered in this report is segmented –
1) By Types Of Antibodies: Monoclonal Antibodies; Polyclonal Antibodies; Biospecific Antibodies; Antibody-Drug Conjugates; Other Types
2) By Therapeutic Area: Oncology; Autoimmune Diseases; Infectious Diseases; Neurodegenerative Disorders; Other Therapeutic Areas
3) By End-User: Hospitals And Clinics; Research Institutes; Pharmaceutical And Biotechnology Companies; Other End-Users
Subsegments:
1) By Monoclonal Antibodies: IgG Monoclonal Antibodies; IgM Monoclonal Antibodies
2) By Polyclonal Antibodies: Serum-Derived Polyclonal Antibodies; Hybridoma-Derived Polyclonal Antibodies
3) By Bispecific Antibodies: Dual-Targeting Antibodies; Single-Chain Variable Fragment (scFv) Antibodies
4) By Antibody-Drug Conjugates (ADCs): Targeted ADCs; Payload Types
5) By Other Types: Nanobodies; Engineered Antibodies
What Trends Are Redefining The Next-Generation Antibody Therapeutics Market Dynamics?
A significant trend gaining traction within the next-generation antibody therapeutics market involves technological progress. Leading firms in the next-generation antibody therapeutics market are concentrating on innovating technologically, including proprietary Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology, to improve protein identification and characterization, thereby enabling more precise and potent treatments. Consequently, these innovations seek to better therapeutic outcomes, lower expenses, and tackle intricate diseases with enhanced accuracy. Molecular Indexing of Proteins by Self-Assembly (MIPSA) is defined as a technology that arranges protein molecules into structured formations, facilitating improved analysis and measurement. This technology boosts the sensitivity and accuracy of protein detection, proving valuable in both research and diagnostic applications. For example, in January 2024, Infinity Bio, Inc., a biotechnology company based in the US, introduced an advanced antibody profiling platform leveraging MIPSA technology for efficient, economical analysis of immune responses, with the goal of deepening disease comprehension and tailoring treatment approaches.
Who Are The Core Companies Influencing The Next-Generation Antibody Therapeutics Market Landscape?
Major companies operating in the next-generation antibody therapeutics market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Moderna Inc., BioNTech SE, Regeneron Pharmaceuticals Inc., Biogen Inc., Celgene Corporation, Lonza Group AG, Catalent Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics, WuXi Biologics, Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc.
Download The Full Report For Exclusive Market Findings:
What Regional Growth Trends Are Shaping The Next-Generation Antibody Therapeutics Market Outlook?
North America was the largest region in the next-generation antibody therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request A Customized Version Of The Next-Generation Antibody Therapeutics Market Report:
https://www.thebusinessresearchcompany.com/customise?id=12678&type=smp
Browse Through More Reports Similar to the Global Next-Generation Antibody Therapeutics Market 2025, By The Business Research Company
Antibody Drug Conjugates Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report
Next Generation Sequencing Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/next-generation-sequencing-global-market-report
Next Generation Data Storage Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/next-generation-data-storage-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model